ATLANTA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) complied with federal securities laws. On January 28, 2026, REGENXBIO announced it “received communication from the U.S. Food and Drug Administration (“FDA”) that the Company’s Investigational New Drug applications for both its Phase I/II trial evaluating RGX-111 for Mucopolysaccharidosis type I and its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis ...

Core Points - VYNE Therapeutics Inc. announced a clinical hold on its Phase 1b study of VYN202 for moderate-to-severe plaque psoriasis due to observed testicular toxicity in dogs from a non-clinical toxicology study [1][2] - The company has suspended all screening, enrollment, and patient dosing in the Phase 1b trial and aims to resolve the clinical hold with the FDA as soon as possible [2] - The clinical hold does not affect VYNE's ongoing Phase 2b trial of repibresib gel for nonsegmental vitiligo, with top-line results expected mid-year [3] - The CEO of VYNE expressed disappointment over the clinical hold but emphasized the priority of patient safety and the intention to work closely with the FDA [4] - VYNE is focused on developing differentiated therapies for chronic inflammatory and immune-mediated conditions, utilizing its proprietary BET inhibitors [4]